OGN

Organon Bolsters Research & Development Expertise with Two Leadership Appointments

Retrieved on: 
Tuesday, September 5, 2023
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, General Health, Health, Clinical Trials, MSD, Medical Affairs Bureau, Shionogi, Takeda, Head, Private practice, Attention, CMO, OGN, Research and development, Clinical trial, Patient, AbbVie, Johnson & Johnson, NYSE, Medical device, Merck, Organon

Both positions report directly to Sandra Milligan, M.D., J.D., Head of Research and Development.

Key Points: 
  • Both positions report directly to Sandra Milligan, M.D., J.D., Head of Research and Development.
  • Dr. Arjona Ferreira brings over two decades of clinical research and development experience and a strong background in women’s health.
  • As the company’s CMO, Dr. Arjona Ferreira will be responsible for leading Organon’s Global Clinical Development, Clinical Trial Operations, Global Biostatistics, and Global Pharmacovigilance and Safety Science teams.
  • Prior to joining Takeda, Dr. Owens served as a leader in clinical development and medical affairs at AbbVie, Kimberly Clark, and Johnson & Johnson.

Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Retrieved on: 
Tuesday, August 1, 2023
SB5, Psoriasis Area and Severity Index, Week, OGN, ADL, Psoriasis, Patient, Organon, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Interval (mathematics), NYSE, Food, Pharmaceutical industry, Generic drug, Cmax, Adalimumab

INCHEON, South Korea and JERSEY CITY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira® (adalimumab).

Key Points: 
  • INCHEON, South Korea and JERSEY CITY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira® (adalimumab).
  • The primary objective of the study was to assess the pharmacokinetic similarity between two treatment groups: patients with moderate to severe plaque psoriasis who switched multiple times between Humira (ADL) and high-concentration SB5 versus patients receiving ADL continuously.
  • All 371 patients who were enrolled in the study had no prior treatment with ADL and were treated in this study with ADL during a lead-in period of 13 weeks.
  • HADLIMA was introduced into the U.S. commercial market on July 1, 2023 and is marketed by Organon.

Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023

Retrieved on: 
Monday, July 17, 2023
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Interest, Webcast, NYSE, EDT, OGN, ID, Security (finance), Organon

Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Key Points: 
  • Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
  • Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://events.q4inc.com/attendee/930696972 .

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

Retrieved on: 
Wednesday, July 5, 2023
New Drug Application, NDA, Bacterial vaginosis, Woman, OGN, Sale, SAN, Knowledge, NYSE, Pharmaceutical industry, Organon

“Daré has completed manufacturing validation activities required to support commercial launch.

Key Points: 
  • “Daré has completed manufacturing validation activities required to support commercial launch.
  • To provide for continuity of supply to support a robust commercial launch, additional manufacturing related activities are being performed and Organon and Daré are working towards a 2023 U.S. launch as soon as feasible.
  • In 2022, Daré received a $10.0 million upfront payment from Organon when the license agreement became effective.
  • As Daré previously shared , the New Drug Application (NDA) for XACIATO was supported by positive results from the DARE-BVFREE Phase 3 randomized, multi-center, double-blinded, placebo-controlled clinical trial evaluating XACIATO (formerly known as DARE-BV1) for the treatment of bacterial vaginosis (NCT04370548).

Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals

Retrieved on: 
Tuesday, June 27, 2023
Biotechnology, Professional Services, Other Health, Health, Women, Pharmaceutical, Environmental, Social and Governance (ESG), DEI (Diversity, Equity and Inclusion), Environment, Consumer, Sustainability, United Nations Sustainable Development Group, Promise, Woman, OGN, Sustainable Development Goals, Investment, Water, Biophysical environment, Power, ESG, NYSE, Female, Renewable energy, Birth control, Social, Organon

Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report .

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report .
  • The report highlights the company’s progress on its comprehensive ESG platform, Her Promise, and its related goals, which are in line with the United Nations Sustainable Development Goals (SDGs).
  • “At Organon, our purpose is fueled by the promise held by the four billion women and girls in the world,” said Kevin Ali, Organon CEO.
  • “Our second ESG report, highlighting the company’s first full year of operations, shows its progress toward important goals.

Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health

Retrieved on: 
Wednesday, June 7, 2023
Women, Finance, Banking, Professional Services, Biotechnology, DEI (Diversity, Equity and Inclusion), General Health, Pharmaceutical, Consumer, Health, United Nations Sustainable Development Group, CAF – Development Bank of Latin America, Woman, CAF, OGN, Government, GDP, Investment, Development finance institution, Risk, MOU, Economic development, NYSE, Drug, Organon

Across the globe, tremendous gaps exist in women’s health that can potentially prevent women and thus economies from achieving their full potential.

Key Points: 
  • Across the globe, tremendous gaps exist in women’s health that can potentially prevent women and thus economies from achieving their full potential.
  • Sustainable financing can advance progress in women’s health by mobilizing capital towards initiatives that might not otherwise receive adequate support like increasing access to sexual and reproductive health education and healthcare services.
  • Sustainable financing is one potential solution to address constrained government budgets while catalyzing healthcarei and socioeconomic progress.
  • By using data, Organon is helping governments understand the value sustainable finance can provide to their people and their economies through health-related investments.

Organon To Report First Quarter and Host Conference Call on May 4, 2023

Retrieved on: 
Thursday, April 20, 2023
Health, Consumer, Women, Other Health, General Health, Pharmaceutical, Biotechnology, Interest, Webcast, NYSE, EDT, OGN, ID, Security (finance), Organon

Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Key Points: 
  • Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
  • Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://conferencingportals.com/event/jgIqShwa .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Retrieved on: 
Friday, March 10, 2023
OGN, News, Organon & Co., NYSE, Organon, Cryptocurrency, Private investigator

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).

Key Points: 
  • NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist

Retrieved on: 
Tuesday, March 7, 2023
Other Philanthropy, Women, Medical Supplies, Managed Care, General Health, DEI (Diversity, Equity and Inclusion), Family, Socially Responsible Investing, Social Services, Other Health, Consumer, Environmental, Social and Governance (ESG), Pharmaceutical, Teens, Baby, Maternity, Professional Services, Philanthropy, Other Education, Health, Education, Child, Science, NYSE, Pregnancy, Equity, UNFPA, United Nations Commission on the Status of Women, Equalizer, Inauguration, Environment, International, Division, Communication, SRH, Multimedia, NGO, Investment, OGN, United Nations, Organization, Birth control, Woman, Organon

View the full release here: https://www.businesswire.com/news/home/20230307005176/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230307005176/en/
    Unplanned pregnancies are in part caused by a lack of access to contraceptive information and services.
  • Globally, of the 257 million women who want to avoid pregnancy, almost 67% are not using any contraceptive method.
  • “The staggering number of unintended pregnancies that occur globally each year – nearly half of all pregnancies – require the power of public-private collaboration.
  • In 2022, Organon made a commitment to help prevent 120 million unplanned pregnancies in the world’s least-developed countries by 2030 as part of FP2030 .

Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace

Retrieved on: 
Friday, March 3, 2023
Parity, Woman, Gender, National Employees' Trade Union, Heart, Certification, Sustainable Development Goals, NYSE, Human, Human resources, St. John's International Women's Film Festival, Health, UN, OGN, Environment, Organization, Policy, International Women's Day, Culture, Wig, Sustainable development, Workplace, Nursing, Organon, QC

The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace.

Key Points: 
  • The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace.
  • "This recognition is a strong testament to our ongoing commitment to gender equity in the workplace and beyond," says Michael Casia, President and Managing Director at Organon Canada.
  • "At Organon Canada, our mission is to deliver impactful solutions which help to envision a better and healthier every day for everyone, with a focus on women.
  • To learn more about Organon Canada's vision and values as it relates to diversity, equity, inclusion and belonging, visit organon.com/Canada-en/mission-vision-values/ .